Revance Therapeutics Inc (RVNC)

[DewDiligence]

RVNC fully-diluted shares @10/28/21=89.4M—a decrease of 0.4M since 7/28/21 (#msg-165334281).

As explained on page 42 of the 3Q21 10-Q (https://www.sec.gov/ix?doc=/Archives/edgar/data/1479290/000147929021000165/rvnc-20210930.htm ), the 89.4M figure above consists of: 71.8 basic shares; 4.9M options; 3.8M shares of (already issued) unvested restricted stock awards; and 8.9M shares deriving from the convertible debt issued in Feb 2020. The decrease of 0.4M shares from 7/28/21 to 10/28/21 was due entirely to a decrease in the shares underlying unvested restricted stock.

(Excluding the shares derived from the convertible debt, fully-diluted shares at 10/28/21 were 80.4M.)

Note: RVNC did not sell any shares under the ATM facility during 3Q21 or during 4Q21 through 10/28/21 (the date of the accounting on p.42 of the 3Q21 10-Q).